Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Pramlintide acetate price?Allergan's patent for latisse expired?Xiaflex market launch year?Can lipitor's dosage change cause liver enzyme fluctuations?Patent tenofovir alafenamide gilead?
See the DrugPatentWatch profile for Wegovy
Wegovy Patent Exclusivity Timeline Wegovy, a semaglutide medication for weight management, is developed by Novo Nordisk, a Danish pharmaceutical company. When Does Exclusivity Expire? According to DrugPatentWatch.com [1], the original patent for Wegovy was granted in 2017, and the drug's exclusivity period in the United States began in June 2021. The US Food and Drug Administration (FDA) has approved Wegovy until November 2023. Generic Competition and Biosimilars As the patent approaches expiry, several companies are developing generic versions of Wegovy or biosimilars, which are near-identical copies of the original medication. These alternatives are expected to enter the market after the patent expires. Why Is This Patent Important? Wegovy patent is critical to Novo Nordisk's revenue and market share in the weight management segment. The exclusivity period determines how long Novo Nordisk can maintain its market dominance and pricing power for Wegovy before facing generic competition. Novo Nordisk's Challenging the Patent Novo Nordisk has faced challenges from biosimilar manufacturers, including Coherus Biosciences and Viatris, who have initiated ANDA (Abbreviated New Drug Application) submissions for their respective semaglutide biosimilars before the patent's expected expiry date. Wegovy's Place in the Market Wegovy has become a leading treatment for obesity and weight management, with sales of over $1 billion annually. The loss of exclusivity will lead to increased competition, which may lead to lower prices and greater access to the medication. Pricing and Accessibility Concerns Generic competition could reduce the price of Wegovy, making it more accessible to patients in need of weight management treatment. However, it also raises concerns about access to essential medications for patients with limited financial means. Additional Facts Novo Nordisk plans to continue investing in its manufacturing capacities and research pipelines to maintain its market position in the semaglutide market. [2] Sources [1] DrugPatentWatch.com - patent information for Wegovy [2] Novo Nordisk Annual Report - 2022 [3] Reuters - Novo Nordisk to face generic competition for Wegovy
Other Questions About Wegovy :